The discovery that sulphonylureas can be used to treat neonatal diabetes (NDM) caused by mutations in the KCNJ11 and ABCC8 genes represented a major breakthrough in the management of this rare and difficult condition. The gene discussed is KCNJ11; the disease is neonatal diabetes mellitus.